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Behavioural and dopaminergic 
changes in double mutated human 
A30P*A53T alpha-synuclein 
transgenic mouse model of 
parkinson´s disease
tommi Kilpeläinen, Ulrika H. Julku, Reinis Svarcbahs  & timo t. Myöhänen  *
Alpha-synuclein (aSyn) is the main component of Lewy bodies, the histopathological marker in 
Parkinson’s disease (PD), and point mutations and multiplications of the aSyn coding SNCA gene 
correlate with early onset PD. Therefore, various transgenic mouse models overexpressing native 
or point-mutated aSyn have been developed. Although these models show highly increased aSyn 
expression they rarely capture dopaminergic cell loss and show a behavioural phenotype only at old 
age, whereas SNCA mutations are risk factors for PD with earlier onset. The aim of our study was to re-
characterize a transgenic mouse strain carrying both A30P and A53T mutated human aSyn. Our study 
revealed decreased locomotor activity for homozygous transgenic mice starting from 3 months of age 
which was different from previous studies with this mouse strain that had behavioural deficits starting 
only after 7–9 months. Additionally, we found a decreased amphetamine response in locomotor 
activity and decreased extracellular dopaminergic markers in the striatum and substantia nigra with 
significantly elevated levels of aSyn oligomers. In conclusion, homozygous transgenic A30P*A53T aSyn 
mice capture several phenotypes of PD with early onset and could be a useful tool for aSyn studies.
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease with an 
annual incidence of 160 per 100 000 people over 65 years old1. There are several risk factors including environ-
mental and genetic factors associated with PD. However, less than 10% of PD cases have an identifiable genetic 
cause, thus development of the disease is most likely influenced by both complex genetic and environmental 
risk factors. PD is pathologically characterized by degeneration of dopaminergic neurons in the substantia nigra 
pars compacta (SNPc) and depletion of dopamine (DA) in striatal projections that leads to motor impairment2–5. 
Accumulation of alpha-synuclein (aSyn) in the brain and formation of filamentous inclusions called Lewy bodies 
and Lewy neurites are hallmarks of PD pathophysiology6. Inclusions of insoluble aSyn are also found in the brain 
of patients with Lewy body dementia and multiple system atrophy. The role of aSyn in the pathophysiology of PD 
was emphasized when mutations in the aSyn coding gene (SNCA) were found. The first discovered PD-related 
mutation in the SNCA gene was a point mutation where alanine in position 53 was substituted with threonine 
(A53T) leading to disruption in a helical formation7, and this mutation is associated with familial early onset PD8. 
Later, two more familial forms of early-onset PD associated with point mutations in the SNCA, namely A30P and 
E46K, were found9,10. Furthermore, duplications and triplications in the SNCA gene also increase incidence and 
severity of this disease11,12, further supporting the importance of aSyn in PD pathophysiology. aSyn aggregation 
leads to loss-of-function toxicity, and aggregates, particularly oligomers, damage several cellular organelles, while 
aSyn fibrils can propagate aSyn toxicity by cell-to-cell transfer13. Although, aSyn has been widely studied in the 
context and models of PD, its physiological role is more unclear. It has been suggested that aSyn interacts with 
DA transporter (DAT) which regulates the kinetics of extracellular DA in the synapses14. Aggregation of aSyn 
decreases the expression and membrane trafficking of DAT under normal circumstances indicating that aSyn 
has a role in DAergic neurotransmission15,16. Furthermore, it has been shown that aSyn colocalizes with SNARE 
Division of Pharmacology and Pharmacotherapy/Drug Research Program, Faculty of Pharmacy, University of 
Helsinki, Helsinki, Finland. *email: timo.myohanen@helsinki.fi
open
2Scientific RepoRtS |         (2019) 9:17382  | https://doi.org/10.1038/s41598-019-54034-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
proteins and aSyn aggregation redistributes them leading to decreased DA release in a mouse line expressing 
truncated aSyn17,18.
Transgenic (tg) mice overexpressing human aSyn have been a common tool to study aSyn toxicity and aSyn 
targeting drug therapies. Several mouse lines overexpressing wildtype (wt) aSyn or mutated forms of aSyn 
have been developed but these models mainly lack DAergic neuronal cell loss despite excessive aSyn expres-
sion (reviewed in19). Richfield et al.20 introduced a mouse model expressing double mutated human aSyn gene 
with both A30P and A53T point mutations under the rat tyrosine hydroxylase (TH) promoter (C57BL/6J-Tg
(TH-SNCA*A30P*A53T)39Eric/J) that combined two well-characterized familial site mutations of SNCA to 
model PD. These tg mice expressed human aSyn in cell bodies, axons, and terminals in the nigrostriatal pathway, 
and had decreased locomotor activity at age 7–9 and 13–23 months, and lowered concentration of DA and its 
metabolites in the striatal tissue at age 16–18 months. Similar to several other aSyn tg mice, younger mice did not 
have significant changes in locomotor activity or in striatal DA concentration. However, both A30P and A53T 
familial point mutations in SNCA are a risk factor for early onset PD19 but these features were not captured in the 
earlier study. Therefore, the aim of this study was to breed a homozygous A30P*A53T aSyn tg mouse strain, and 
characterize if this animal model would capture the phenotype of early-onset PD. We designed PCR oligonucleo-
tides and a new genotyping protocol to distinguish between wt, heterozygous, and homozygous animals in order 
to characterize behavioural and DAergic changes in homozygous A30P*A53T aSyn tg mice. Interestingly, we 
found several behavioural and histological changes that were not described in the original publication.
Results
A30P*A53T aSyn tg mice have altered locomotor activity. 22-hour locomotor activity measure-
ments showed differences between C57BL/6J-Tg(TH-SNCA*A30P*A53T)39Eric/J (tg) and wt littermates in 
all age groups (Fig. 1A–F). 3 months old mice did not have statistically significant alteration in overall loco-
motor activity. However, between the second and fifth hour (11–14), there was a trend that tg mice are less 
active compared to wt littermates (Fig. 1A, genotype effect: F1,16 = 3.705, p = 0.072, repeated measures 2-way 
ANOVA). 6 months old mice had statistically significant differences in locomotor activity in three different time 
intervals. Between 12:00 and 14:00, and 22:00 and 00:00 tg mice exhibited lower activity compared to wt litter-
mates (Fig. 1B, 12:00–14:00 genotype effect: F1,26 = 9.982, p = 0.004; 22:00–00:00 genotype effect: F1,26 = 12.986, 
p = 0.001, repeated measures 2-way ANOVA). However, between 17:00 and 20:00 tg mice showed higher loco-
motor activity compared to wt littermates (Fig. 1B, genotype effect: F1,26 = 10.622, p = 0.003, repeated measures 
2-way ANOVA). 9 months old tg mice had significantly lower activity between 12:00 and 14:00, and between 
22:00 and 02:00 compared to wt littermates (Fig. 1C, 12:00–14:00 genotype effect: F1,28 = 9.725, p = 0.004; 22:00–
02:00 genotype effect: F1,28 = 19.213, p = 0.0001, repeated measures 2-way ANOVA), while between 18:00 and 
20:00 tg mice were more active compared to wt littermates (Fig. 1C, genotype effect: F1,28 = 8.924, p = 0.006, 
repeated measures 2-way ANOVA). Th effect was similar but more pronounced than the one seen in the 6 months 
old tg animals. 12 months old tg mice were more active compared to wt littermates during 18:00 and 20:00 period 
(Fig. 1D, genotype effect: F1,35 = 6.620, p = 0.014, repeated measures 2-way ANOVA). However, between 12:00 
and 15:00, and between 22:00 and 02:00 tg mice had decreased activity compared to wt littermates (Fig. 1D, 
12:00–15:00 genotype effect: F1,35 = 5.911, p = 0.029; 22:00-02:00 genotype effect: F1,35 = 6.540, p = 0.015, repeated 
measures 2-way ANOVA). At 6, 9 and 12 months, wt mice had delayed and higher horizontal locomotor activity 
after lights were turned off compared to tg mice (Fig. 1B–D). Interestingly, 18 months old tg mice were more 
active during the dark time between 18:00 and 22:00 (genotype effect: F1,14 = 20.753, p = 0.0004, repeated meas-
ures 2-way ANOVA). Total distance travelled during the first hour of the experiment did not show any differences 
between wt and tg groups except at 12 months the tg animals were more active during the first hour (Fig. 1F, 
t = 2.478, p = 0.023, Student’s t-test).
During the 22-hour locomotor activity monitoring, differences were found between tg and wt mice in total 
distance travelled, vertical count, jump count, and average speed (Fig. 2A–D). Total distance travelled was sig-
nificantly lower in 9 (Fig. 2A t = 2.28, p = 0.0301, Student’s t-test) and significantly increased in 18 (Fig. 2A 
t = 2.996, p = 0.0096, Student’s t-test) months old tg mice compared to wt mice. Vertical counts was already sig-
nificantly lower in 3 (Fig. 2B, t = 2.54, p = 0.0218, Student’s t-test) and 6 (Fig. 2B, t = 4.409, p = 0.0002, Student’s 
t-test) months old tg mice. However, 12 months old tg mice had more vertical counts compared to wt littermates 
(Fig. 2B, t = 2.068, p = 0.045, Student’s t-test). Tg mice also had a significantly lower jump count at 3 (Fig. 2C, 
t = 3.835, p = 0.0013, Student’s t-test), 6 (Fig. 2C, t = 7.062, p < 0.0001, Student’s t-test) and 9 months (Fig. 2C, 
t = 2.785, p = 0.0093, Student’s t-test). Additionally, tg mice had a significantly lower average speed during the 
ambulatory episodes in all age groups (Figs. 2D, 3 (t = 6.028), 6 (t = 7.356), 12 (t = 8.311) and 18 (t = 5.718) 
months p < 0.0001; 9 months, t = 3.328, p = 0.0023, Student’s t-test).
A30P*A53T aSyn tg mice have altered amphetamine-induced locomotor activity. 90 min 
amphetamine-induced locomotor activity was assessed to evaluate differences in response to systemic amphet-
amine administration. No differences were observed between tg and wt mice at 3 and 12 months while at the 
9 month time-point tg animals were more active compared to wt littermates only during the first 15 minutes 
after amphetamine administration (Fig. 3C, genotype effect: F1,30 = 4.790, p = 0.037, repeated measures 2-way 
ANOVA). However, 6 months old tg animals were significantly more active during the whole 90 minute period 
compared to wt littermates (Fig. 3B, genotype effect: F1,32 = 9.649, p = 0.004, repeated measures 2-way ANOVA). 
In 18 months old mice, a similar effect was observed (Fig. 3E, genotype effect: F1,15 = 4.632, p = 0.047, repeated 
measures 2-way ANOVA). In addition, total traveled distance during the first 5 minutes was significantly 
increased in 3 (Fig. 3F, t = 2.879, p = 0.01, Student’s t-test), 6 (Fig. 3F, t = 3.701, p = 0.0008, Student’s t-test), 12 
(t = 2.306, p = 0.026, Student’s t-test) and 18 months (Fig. 3F, t = 2.429, p = 0.028, Student’s t-test) old tg mice 
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compared to wt littermates. A similar effect was also observed in the 22-hour locomotor activity recordings but 
the effect was more noticeable in amphetamine-induced locomotor activity.
Microdialysis and HPLC analysis of the nigrostriatal pathway of A30P*A53T aSyn tg mouse. 
The impact of the mutant aSyn transgene in the striatal DAergic function was studied in 12 and 18 month old 
tg mice and their wt littermates by microdialysis and tissue high-performance liquid chromatography (HPLC) 
analysis. In microdialysis, baseline level of extracellular striatal DA, its metabolites dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA), or gamma-aminobutyric acid (GABA) were not changed statistically 
Figure 1. 22 hour locomotor activity was altered between aSyn transgenic (tg) and wild type (wt) littermates 
in all age groups. At 3 months, significant changes between tg and wt animals were not seen (A). 6, 9, and 
12 months old tg mice were more active compared to wt littermates right after the lights were turned off but 
less active than wt mice between 22:00 and 1:00 (B–D). 18 months old tg mice were more active during the 
dark time compared to wt littermates (E). When comparing locomotor activity during the first hour of the 
locomotor experiment, tg mice showed increased activity only at the age of 12 months (F). Data are expressed as 
mean ± SEM, n = 7–23. Repeated measures 2-way-ANOVA, (A–E); Student’s t-test (F); *p < 0.05, **p < 0.005, 
***p < 0.001.
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significantly in the 12 months old mice (Fig. 4, DA: p = 0.224; DOPAC + HVA: p = 0.322; GABA: p = 0.637, 
Student’s t-test) or in the 18 months old mice (Fig. 4, DA: p = 0.884; DOPAC + HVA: p = 0.901, GABA: p = 0.668 
Student’s t-test). Extracellular concentration of 5-hydroxyindoleacetic acid (5-HIAA) was increased in the 12 
and 18-month old tg mice (Fig. 4C, 12-months, t = 2.467, p = 0.023; 18-months, t = 2.396, p = 0.032, Student’s 
t-test). Amphetamine-induced DA release elevated striatal extracellular DA concentration less in 12-month old tg 
mice than in wt littermates with 30 µM d-amphetamine sulphate concentration (Fig. 4E, F1, 20 = 4.988, p = 0.037, 
repeated measures ANOVA), and there was a similar trend with 10 µM d-amphetamine sulphate (Fig. 4E, F1, 
20 = 3.286, p = 0.085, repeated measures ANOVA). A similar difference was not observed in the 18-month group 
(Fig. 4F, 10 µM d-amphetamine sulphate: F1, 12 = 0.573, p = 0.463; 30 µM d-amphetamine sulphate: F1, 12 = 0.470, 
p = 0.506, repeated measures ANOVA).
HPLC analysis revealed that striatal tissue concentrations of DA (Fig. 5A, p = 0.528, Student’s t-test), its 
metabolites DOPAC and HVA (Fig. 5B, p = 0.850, Student’s t-test), 5-HT (Fig. 5C, p = 0.273, Student’s t-test), its 
metabolite 5-HIAA (Fig. 5D, p = 0.127, Student’s t-test), GABA (Fig. 5E, p = 0.218, Student’s t-test) and glutamate 
(Fig. 5F, p = 0.553, Student’s t-test) were not significantly altered in the 12 months old mice. Striatal concentration 
of DA was lower in the 18 months old tg mice compared to wt littermates (Fig. 5A, t = 2.639, p = 0.019, Student’s 
t-test) and there was a similar trend seen for the DA metabolites (Fig. 5B, p = 0.067, Student’s t-test). Additionally, 
5-HT (Fig. 5C, t = 4.283, p = 0.0008, Student’s t-test), GABA (Fig. 5E, t = 2.631, p = 0.020, Student’s t-test), and 
glutamate (Fig. 5F, t = 2.546, p = 0.023, Student’s t-test) were significantly elevated in the 18 months old tg mice. 
Striatal tissue concentration of 5-HIAA was not changed in the 18 months old mice (Fig. 5D, p = 0.520, Student’s 
t-test). Striatal GABA and glutamate were decreased in 18 months old wt mice compared to 12 months old wt 
mice (Fig. 5E, GABA: t = 2.647, p = 0.017; Fig. 5F, GLU: t = 2.508, p = 0.023, Student’s t-test), but a similar phe-
nomenon was not observed in the tg mice.
A30P*A53T aSyn tg mice have reduced TH immunoreactivity and increased aSyn oligomer-specific 
staining in the Snpc and striatum. Optical density (OD) analyses of TH and aSyn oligomer-specific immuno-
reactivity was quantified in the nigrostriatal tract of wt and tg mice (Fig. 6A–E). OD analyses revealed significant dif-
ferences in the TH immunoreactivity in the striatum and SNpc. Both 12 and 18 months old tg mice had decreased TH 
immunoreactivity in both striatum (Fig. 6B, 12 months: t = 3.625, p = 0.0012; 18 months: t = 3.139, p = 0.0072, Student’s 
Figure 2. Comparison of total distance travelled, vertical counts, jump count, and average speed during 22 h 
locomotor activity measurements between aSyn transgenic mice (tg) and wild type littermates (wt). Total 
distance travelled was decreased in 9 months and increased in 18 months old tg mice compared to wt mice (A). 
3 and 6 months old tg mice showed significantly less vertical counts compared to littermates (B). 12 old months 
tg mice had more vertical counts compared to wt mice (B). Jump counts were significantly lower in 3, 6, and 9 
months old tg mice compared to wt littermates (C). Average speed of tg mice was significantly lowered in all age 
groups (D). Data are expressed as mean ± SEM, n = 7–23. Student’s t-test, *p < 0.05, **p < 0.005, ***p < 0.001, 
****p < 0.0001.
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t-test) and SNpc (Fig. 6C, 12 months: t = 2.499, p = 0.019; 18 months: t = 3.175, p = 0.0067, Student’s t-test) compared 
to wt littermates. Accumulation of aSyn oligomers was identified by immunohistochemistry (IHC) in the SNpc and 
striatum. Both 12 and 18 months old tg mice had significantly increased immunoreactivity for aSyn oligomers in stria-
tum (immunostained by aSynO5 antibody; Fig. 6A,D, 12 months: t = 6.36, p < 0.0001; 18 months: t = 7.716, p < 0.0001) 
and in SNpc (immunostained by aSynO5 antibody; Fig. 6A,E, 12 months: t = 8.084, p < 0.0001; 18 months: t = 11.53, 
p < 0.0001). OD analysis for total aSyn in the striatum revealed no significant differences in immunoreactivities in 12 
and 18 months old tg mice compared to wt mice (see Supplementary Fig. S1).
Figure 3. Amphetamine-induced locomotor activity was increased in the aSyn transgenic animals (tg) 
compared to wild-type (wt) littermates. After amphetamine administration, increased activity in tg mice was 
seen at the 6 and 18 month time-points, while only initial locomotor activity was increased in 9 months old tg 
animals (A–E). Total travelled distance of tg mice was increased in all age groups during the initial 5 minutes 
of the locomotor activity test compared to wt littermates (F). Data are expressed as mean ± SEM; n = 7–23. 
Repeated measures two-way ANOVA(A–E), Student’s t-test (F); *p < 0.05, **p < 0.01, ***p < 0.001.
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Discussion
In this study, our aim was to perform additional behavioural and biochemical characterization of the homozy-
gous C57BL/6J-Tg(TH-SNCA*A30P*A53T)39Eric/J tg mice line and establish whether the mouse strain gen-
erates aSyn aggregate accumulation in the nigrostriatal tract. Our results show that homozygous tg mice had 
Figure 4. Striatal extracellular concentrations of dopamine (DA), its main metabolites DOPAC and HVA, 
5-HIAA, and GABA were measured in the 12 months old and 18 months old wildtype (wt) and aSyn transgenic 
(tg) mice by microdialysis. Baseline level of DA (A), its metabolites (B), or GABA (D) were not changed but 
5-HIAA was increased in both 12 months old and 18 months old tg mice (C). Amphetamine-induced increase 
in extracellular dopamine was lowered in the 12 months old tg mice with 30 µM d-amphetamine sulphate 
(AMPH) and there was a similar trend with 10 µM AMPH (E) but there was no difference between 18 months 
old mice (F). Data are expressed as mean ± SEM; 12 months: n = 10–12/group, 18 months: n = 7–8/group. 
Student’s t-test (A-D), repeated measures ANOVA (E-F); *p < 0.05.
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significant differences in locomotor activity in all age groups starting from 3 month-old animals, altered amphet-
amine response, and increased aSyn oligomer levels and decreased TH immunostaining in the nigrostriatal path-
way. In an earlier study by Richfield et al.20 with the same mouse strain, the tg mice had age-dependent changes 
Figure 5. 18 months old aSyn transgenic (tg) animals showed changes in DA, its metabolites, 5-HT, GABA 
and glutamate in the striatum. Striatal tissue concentrations of neurotransmitters and their metabolites were 
measured in the 12 months and 18 months old tg mice and their wild-type (wt) littermates. There was no 
alteration in neurotransmitters or their metabolites in the 12 months old mice (A–F). Dopamine was decreased 
in the striatum of 18 months old tg mice compared to wt littermates (A) and there was a similar trend in the 
dopamine metabolites (B). 5-HT (C), GABA (E) and glutamate (F) levels were increased in 18 months old tg 
mice but 5-HIAA was not changed (D). GABA (E) and GLU (F) had an age-dependent decrease in Wt mice 
but a similar phenomenon was not observed in other neurotransmitters in tg mice. Data are expressed as 
mean ± SEM; 12 months: n = 10–12/group, 18 months: n = 8/group. Student’s t-test, *p < 0.05; ***p < 0.001.
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in locomotor activity starting from 7 months of age, significantly later than in our study. Therefore, we propose 
that a genotyping protocol that was able to separate heterozygous and homozygous mice was needed to generate 
homozygous animals.
Figure 6. aSyn transgenic (tg) mice had significantly decreased TH and increased oligomer specific aSyn 
(aSyn OS) immunoreactivity in the striatum (STR) and substantia nigra (SN). Representative images of TH 
and aSyn OS staining from the striatum and substantia nigra of 12 and 18 month old wt and tg mice (A). TH 
optical density (OD) was significantly decreased in the STR and SN of 12 and 18 month old tg mice (B,C). OD 
of aSyn OS was significantly increased in both STR and SN at 12 and 18 months (D,E). Data are expressed as 
mean + SEM; n = 8–18. Student’s t-test,* p < 0.05, **p < 0.005, ****p < 0.0001.
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Our detailed analysis of locomotor activity revealed that tg mice had decreased dark time activity but their 
highest activity period was shifted earlier compared to wt mice indicating abnormal locomotor behaviour. 
Interestingly, the most distinct differences in vertical and jump counts were observed in 3 and 6 months old 
animals, which could be considered to model motor symptoms of early-onset PD. However, at 12 months of age, 
the difference was not as clear as at earlier time points, and at 18 months tg mice were hyperactive in the loco-
motor test compared to wt littermates. This has been described earlier with A53T-aSyn overexpression tg mice 
strains that have shown to exhibit hyperactivity and anxiety, explained by alterations in function of DAT and an 
increased amount of D1 receptors21–23. Additionally, we observed significantly elevated glutamate levels in the 
striatal tissue of 18 months old tg mice compared to wt littermates which could partly explain the hyperactivity. It 
has been reported that the C57BL/6 mice strain has reduced motor activity at 12 and 22 months of age compared 
to 3 months old animals24, supporting reduced motor activity seen in 18 months old wt animals.
Richfield´s study (2002)20 demonstrated a reduced locomotor response to amphetamine in tg mice, how-
ever our study was contrary since 6, 9, and 18 months old tg mice had an increased response to amphetamine 
in the locomotor activity assay compared to wt littermates. Increased amphetamine-induced locomotor activ-
ity and decreased amphetamine-induced DA release in tg mice can indicate dysfunction of DAT. Interestingly, 
elevated amphetamine-induced DA release was only observed in 12 months old tg mice compared to wt litter-
mates but not in 18 months old tg mice. This can be explained by the finding that the wt mice had decreased 
amphetamine-induced DA release at 18 months old compared to 12 months old wt mice, indicating that 
age-related changes in DAergic function in wt mice could cover the difference that was observed between the 12 
months old wt and tg mice. This promotes the role of aSyn aggregation and toxicity in this mouse model since 
aSyn is known to regulate the function of DAT. In its normal state, aSyn is considered as a negative regulator of 
DAT and aSyn overexpression has been shown to modify basal and amphetamine-induced DA efflux16.
The earlier study also reported that striatal tissue concentrations of DA, DOPAC, and HVA were declined in 
16–18 months old tg mice compared to wt littermates20. This was consistent with our study as the same effect was 
seen for 18 months old mice. Striatal DA was not yet changed in 12 months old tg mice compared to wt litter-
mates although striatal and nigral TH were already decreased at 12 months. However, impairment in DAergic 
function of 12 months old mice was also observed in the microdialysis experiment as amphetamine-induced DA 
release was decreased and behaviour altered in tg mice compared to wt mice. Previous studies have shown that 
aSyn binds to TH25 and A53T mutated aSyn and aSyn aggregation and phosphorylation abolishes aSyn’s impact 
on TH26,27. Therefore, the elevated level of aSyn oligomers seen in tg mice could possibly explain reduced TH. 
Additionally, striatal tissue concentrations of 5-HT and GABA were increased which may arise from decreased 
DA regulation28. As a further support for this, striatal microdialysis revealed elevated baseline levels of 5-HIAA 
in tg mice compared to wt mice indicating increased 5-HT metabolism. Age-dependent decreases in striatal 
GABA and glutamate concentrations were observed in wt mice but not in tg mice. Similar findings in wt mice 
have been reported earlier by29. Decreased striatal DA can increase GABA and glutamate since DA downregulates 
striatal GABA and glutamate via DA receptor D228,30,31. Additionally, accumulation of aSyn has been reported to 
induce enlargement of glutamatergic nerve terminals in the mouse striatum32. In conclusion, decreased DAergic 
function combined with the effect of aSyn on glutamatergic neurons is probably causing the difference in striatal 
GABA and glutamate between 18 months old wt and tg mice.
After aSyn aggregation was revealed as a potential key player in PD pathophysiology, several tg mouse lines 
overexpressing human aSyn with a A30P or A53T point mutation have been described. Mice expressing A30P 
aSyn have, in several studies, failed to show differences in locomotor activity, and in DA and TH levels despite 
accumulation of aSyn in several brain regions33–35. A53T mutant aSyn expressing mice usually have more severe 
motor impairments starting at older age, but malfunction of the DAergic system has not been clearly deter-
mined36–38. This has been one of the major problems when using aSyn tg mice since they do not model the 
most important feature in PD, the degeneration of DAergic system, very effectively. Additionally, these aSyn 
point mutations are a risk factor for early onset PD which occurs before the age of 40 to 50 years in humans39, 
and generally behavioural deficits are seen only in aged tg animals (>12 months). Our study demonstrated that 
A30P*A53T aSyn tg mice did not only have early behavioural changes but also changes in their DAergic system 
and a decreased amount of TH positive cells compared to wt littermates. These effects are most likely caused by 
toxicity from increased aSyn oligomers40 that we reported here in 12- and 18-month age groups. Behavioural 
changes indicate that aSyn toxicity starts earlier since locomotor deficits were already observed in 3 months old 
tg mice, and another double mutant A30P*A53T aSyn mouse line with a different promoter (Thy-1 promoter) 
described motor impairment starting from 3 months41, similar to our findings. Although A30P and A53T double 
mutation in SNCA has not been described clinically, our results indicate that this models early onset PD better 
than other tg mouse models.
In conclusion, there is still a lack of a mouse model for PD that displays motor and non-motor deficits typ-
ical for PD, alterations in the DAergic system and DAergic cell loss together with aSyn propagation and for-
mation of aSyn-rich Lewy bodies. Such a research tool would be particularly critical when developing novel 
disease-modifying therapies targeting causes of PD. Our current study with homozygous double mutant 
A30P*A53T aSyn tg mice does not fulfil all of these requirements but it has early onset and age-dependent 
changes in locomotor activity and in the striatal DAergic function together with aSyn oligomer formation, and it 
could be a useful tool to model early onset PD with familial SNCA mutations.
Methods
Animals. Male C57BL/6J-Tg(TH-SNCA*A30P*A53T)39Eric/J (The Jackson Laboratory, USA) mice were 
housed under standard laboratory conditions (12 h light/dark cycle; room temperature, 23 ± 2 °C; relative 
humidity 50 ± 15%) in individually ventilated cages (Mouse IVC Green Line, Techniplast, Italy) with bedding 
(Aspen chips, 5 × 5 × 1 mm; 4HP, Tapvei, Estonia), nesting material (Aspen strips; PM90L, Tapvei), and Aspen 
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brick (100 × 20 × 20 mm; Tapvei). Mice had access to chow food (Teklad 2016, Envigo, Huntingdon, UK) and 
filtered and irradiated water ad libitum. The experiments were performed according to European Communities 
Council Directive 86/609/EEC and were approved by the Finnish National Animal Experiment Board 
(ESAVI/441/04.10.07/2016).
Genotyping. While we bred tg mice with wt mice to create homozygous mice, we found that homozygous 
male animals have a phenotypical feature where length of hair is much longer compared to the heterozygous 
and wt animals (Supplementary Fig. S2). Homozygous mice with the long-haired phenotypical feature and wt 
littermates were selected for sequencing. Sequencing service and genotyping primer design for the differentiation 
of the wt, heterozygous, and homozygous tg animals was provided by the University of Helsinki Genomic Core 
facility (Helsinki, Finland). Primer pairs provided were tested and all of the PCR products were sequence verified 
by the University of Helsinki Genomic Core facility. List of the best genotyping primer pairs and sequences can be 
found in Table 1. Routine DNA extraction and PCR were performed using REDExtract-N-Amp™Tissue PCR kit 
(#XNAT-1000RXN, Sigma-Aldrich, Saint Louis, MO, USA) with touchdown PCR cycling conditions provided in 
Table 2 and PCR product size was verified by agarose gel electrophoresis.
tissue processing. At the age of 12 or 18 months mice were sacrificed by cervical dislocation followed by 
dissection of the whole brain. The hemispheres were separated by using a brain matrix. The left hemispheres were 
frozen in isopentane on dry ice to collect striatal and nigral tissue samples for HPLC analysis as described in42 
The right hemispheres were postfixed for 24 h in fresh 4% paraformaldehyde (PFA) at +4 °C and transferred to 
10% sucrose in PBS (pH 7.4; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) overnight at +4 °C. 
On the next day, tissue was transferred to 30% sucrose solution in PBS until brains sank. Brains were frozen on 
dry ice and were kept at −80 °C until sectioning. Frozen brains were sectioned as 30 μm free-floating sections on 
a cryostat (Leica CM3050) and kept in a cryoprotectant solution (30% ethylene glycol and 30% glycerol in 0.5 M 
phosphate buffer).
Immunohistochemistry (IHC). Tyrosine hydroxylase (TH) IHC was done as described in43. In short, 
after blocking endogenous peroxidase activity sections were incubated for 30 min in 10% normal goat serum 
to block nonspecific binding, after which the sections were incubated overnight in rabbit anti-TH primary 
antibody (1:2000; AB152, RRID:AB_390204, Merck, Darmstadt, Germany). Subsequently, the sections were 
placed in goat anti-rabbit biotin-conjugated secondary antibodies (1:500; BA1000, RRID:AB_2313606, Vector 
Laboratories, Peterborough, UK). The signal was enhanced with the avidin– biotin complex method (Standard 
Vectastain ABC kit, RRID: AB_2336819, Vector Laboratories) and visualized with 3,3′-diaminobenzidine 
(DAB). Oligomer-specific -aSyn IHC was performed as described in43 using the Basic Vector Mouse on Mouse 
Nr. Primer sequences
PCR 
product, bp Comments
1
Forward:
5′-ACAGCGAAAGTATCATTCATC-3′
Reverse:
5′-AACTGATAGAGGCTGTTTGG-3′
1190
Positive if construct has been 
inserted in chromosome 5 
from position ~91496672→
2
Forward:
5′-ATCTTGGCTCACTGCAATC3′
Reverse:
5′-CTTCTCTCTAGTGTGCAAAGC-3′
849
Positive if construct has been 
inserted in chromosome 5 
from position ← 91514836 ~
3
Forward:
5′-GTGTCACTTCTTAGCATAACG-3′
Reverse:
5′-CTTCTCTCTAGTGTGCAAAGC-3′
480 Positive if chromosome 5 as in original reference
4
Forward:
5′-ATCTTGGCTCACTGCAATC-3′
Reverse:
5′-AACTGATAGAGGCTGTTTGG-3′
1007 Positive if double construct of TH promoter and SNCA exists
Table 1. Primer pairs and PCR product information for TH-SNCA*A30P*A53T genotyping.
Step Temperature (°C) Time (min)
1. Initial denaturation 94 °C 3 min
2. Denaturation 94 °C 0:30 min
3. Annealing 60 °C, −0,3 °C per cycle 0:30 min
4. Extension 72 °C 1:30 min
Go to step 2 33x 
times
5. Final extension 72 °C 10 min
6. Hold 4 °C ∞
Table 2. Cycling parameters used to genotype TH-SNCA*A30P*A53T mice.
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(M.O.M.) Immunodetection Kit (BMK-2202, RRID:AB_2336833, Vector Laboratories). In short, after blocking 
endogenous peroxidase activity, sections were incubated for 30 min in M.O.M. Mouse Ig Blocking Reagent to 
block nonspecific binding, and 5 min in M.O.M. diluent, and transferred overnight in mouse anti-human aSyn 
oligomer-specific primary antibody (1:200 in M.O.M. diluent; AS132718, RRID: AB_2629502, Agrisera, Vännäs, 
Sweden). The sections were then incubated with goat-anti-mouse HRP-conjugated secondary antibody (dilution, 
1:300 in M.O.M. diluent, catalog #31430, RRID:AB_228307, Thermo Fisher Scientific, Grand Island, NY, USA) 
and visualized with DAB.
Microscopy and optical density analyses. The optical densities (ODs) of TH and oligomer-specific aSyn 
from striatum and SNPc were determined as described earlier in43. Digital images were scanned at 40x magnifi-
cation with a Pannoramic Flash II Scanner (3DHISTECH, Budapest, Hungary), and three coronal sections from 
each mouse were processed for further analyses with Pannoramic Viewer (version 1.15.3. RRID:SCR_014424, 
3DHISTECH). Images were converted to grayscale and inverted, and line analysis tools for striatum or freehand 
for SN in ImageJ (1.48b; RRID:SCR_003070, NIH) was used to measure the OD of immunoreactivity. Corpus 
callosum was used to subtract the background optical density of each section and then normalized to the control 
mice.
Behavioral assessments. Locomotor activity was measured every three months from 3 to 12 months and 
18 months using automated open field locomotor activity chambers (Activity monitor, SOF-812, Med Associates 
inc, Georgia, USA). Total photobeam breaks were recorded for 22 h (starting at 10:00) for horizontal, vertical, and 
ambulatory movements. Amphetamine-induced locomotor activity was assessed every third month. Mice were 
habituated in locomotor boxes for 30 minutes before amphetamine (3 mg/kg i.p) was administered. Locomotor 
activity was measured for 90 minutes immediately after the amphetamine administration.
Surgical procedures for microdialysis. Guide cannula (AT4.9.iC, AgnTho’s, Sweden) for microdialysis 
was inserted into the left striatum at 0.6 mm anterior, 1.8 mm lateral, and 2.7 mm below the dura (stereotaxic 
coordinates according to44 in a stereotaxic operation as described in Julku et al.42. The guide cannula was fastened 
to the skull with dental cement (Aqualox, Voco, Germany) and two stainless steel screws (1.2 × 3 mm, DIN84, 
Helsingin Ruuvihankinta, Finland). Mice were anesthetized with isoflurane (4% induction, 1.5–2.0% mainte-
nance; Attane vet 1000 mg/g, Piramal Healthcare, UK). Buprenorphine (0.1 mg/kg s.c.; Temgesic 0.3 mg/mL, 
Reckitt Benckiser Healthcare, UK) was given before the operation and 5–6 h after the surgery, and carprofen 
(5 mg/kg s.c.; Norocarp vet 50 mg/mL, Norbrook Laboratories Ltd, Ireland) was given immediately after the sur-
gery and 24 h after the surgery to relieve post-operative pain.
Microdialysis. Microdialysis was performed in the 12 months old and 18 months old tg mice and their wt 
littermates as described earlier in42. Shortly, a microdialysis probe (1-mm cuprophan membrane, o.d. 0.2 mm, 
6 kDa cut-off; AT4.9.1.Cu, AgnTho’s) was inserted into the guide cannula 2 h before the experiment, and the probe 
was perfused with a modified Ringer solution (147 mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 mM MgCl2, and 
0.04 mM ascorbic acid) at a flow rate of 2.0 μL/min. Four baseline samples were collected (20 min/40 μL/sample) 
after the stabilization period. After the collection of baseline samples, the probe was perfused 2 × 20 min with 
10 μM and 30 μM d-amphetamine sulphate with 2 × 20 min recovery time between the concentrations. The con-
centrations of DA, its metabolites, DOPAC and HVA, and 5-HIAA as well as GABA in dialysates were measured 
using the HPLC methods that have been described earlier in42.
Tissue HPLC analysis. Striatal tissue samples were punched below corpus callosum +0.74 mm from bregma 
to 2 mm depth by using sample corer (i.d. of 2 mm) with a plunger (Stoelting Co, Wood Dale, IL, USA) on a cry-
ostat (Leica CM3050). Tissue processing was done as earlier described in42. The concentration of DA, its metabo-
lites DOPAC and HVA, 5-HT, its metabolite 5-HIAA, GABA and glutamate in the tissue samples of striatum were 
analyzed with an HPLC as earlier described in42. The concentrations were calculated as nanograms per milligram 
of brain tissue.
Data availability
All materials, data and associated protocols are available to readers.
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